A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma

Acta Oncologica
Antonio RuedaGotel and Geltamo

Abstract

Relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT) remains a challenge. For these patients treatments with different mechanisms of action rather than classical chemotherapy are needed. Patients with R/R cHL after ASCT were recruited in a phase II trial (EUDRA CT: 2009-016588-12). Lenalidomide was administered at 20 mg/day for 21 days and cyclophosphamide at 50 mg/day for 28 days (cycles every 28 days). Dose escalation for lenalidomide was permitted. In 2009 we considered that this treatment would be promising if response rate were over 60% and a Simon two-stage binomial design was used to calculate the sample size. A total of 46 patients were planned but the trial would be stopped if less than seven responses after four cycles were obtained in the first 16 patients. The trial was closed early because only five responses were observed after four cycles in the first 16 patients included. Median age was 34 years (18-77). The median number of previous lines was five (2-6). At inclusion, 10 patients were primary refractory and 11 refractory to the last therapy. A total of 110 cycles were administered, with grade≥3 toxicity in 43 cycles (39%). One non-neutropenic patient de...Continue Reading

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ColleoniA Goldhirsch
Mar 28, 2003·The Journal of Infectious Diseases·Patrick A J HaslettGilla Kaplan
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott D YoungColin J Germond
Apr 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BartlettUNKNOWN Cancer Leukemia Group B
Jan 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joseph A BlansfieldSteven K Libutti
Oct 30, 2009·British Journal of Haematology·Boris BöllRalph Naumann
Oct 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Dec 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison J MoskowitzCraig H Moskowitz

❮ Previous
Next ❯

Citations

Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Rajendra Gharbaran
Mar 21, 2017·Leukemia & Lymphoma·Sven Borchmann, Bastian von Tresckow
Jul 6, 2021·Frontiers in Pharmacology·Florian LükeDaniel Heudobler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.